Human ITAC (CXCL11) Recombinant

///Human ITAC (CXCL11) Recombinant

Human ITAC (CXCL11) Recombinant

$70.00$2,700.00

SKU: RKO14625 Category: Tags: , , , , , , , ,

accession O14625


Source Optimized DNA sequence encoding Human ITAC (CXCL11) mature chain was expressed in Escherichia Coli.
Molecular weight Human ITAC, generated by the proteolytic removal of the signal peptide and propeptide and has a calculated molecular mass of approximately8 kDa. RecombinantCXCL11 is a monomeric protein consisting of amino acid residue subunits and migrates as an approximately8 kDa protein under non-reducing conditions and reducing conditions in SDS-PAGE.
Purity >98%, as determined by SDS-PAGE and HPLC
Biological Activity Determined by its ability to chemoattract human T cells using a concentration range of.0-10.0 ng/ml.

Protein Sequence MSVKGMAIAL AVILCATVVQ GFPMFKRGRC LCIGPGVKAV KVADIEKASI MYPSNNCDKI EVIITLKENK GQRCLNPKSK QARLIIKKVE RKNF
Endotoxin Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than.1 ng/µg(1EU/µg).
Presentation Recombinant ITAC was lyophilized from a.2 μm filteredmM PB,100mM NaCl solution pH.5.
Reconstitution A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than.1 mg/mL. This solution can then be diluted into other buffers.
Storage The lyophilized protein is stable for at least years from date of receipt at -20° C. Upon reconstitution, this cytokine can be stored in working aliquots at° -° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles.
Usage This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.


Interactor P51677
Interactor P49682
Biological Process Chemotaxis
Biological Process Inflammatory-response
Molecular function Cytokine

Methods

ERK1/2 activation in NB cell lines.

CXCL11
  • Immunobloting of phospho-ERK (pERK) and total ERK in transduced cells, treated with 100 ng/ml human recombinant CXCL12, in presence or in absence of 1 µM of the CXCR4 blocker TN14003, 100 ng/ml human recombinant CXCL11.